-+ 0.00%
-+ 0.00%
-+ 0.00%

Scotiabank Maintains Sector Outperform on Alnylam Pharmaceuticals, Raises Price Target to $450

Benzinga·08/01/2025 20:43:07
Listen to the news
Scotiabank analyst Greg Harrison maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Sector Outperform and raises the price target from $342 to $450.